Quantification of sertraline maternal/fetal ratio and amniotic fluid concentration using a pregnancy physiologically based pharmacokinetic model
British Journal of Clinical Pharmacology · 2025
DOI: 10.1111/bcp.15826 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von David Lartey und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA. Hauptthemen laut MEDLINE: Sertraline, Selective Serotonin Reuptake Inhibitors, Models, Biological, Amniotic Fluid. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: U.S. Food and Drug Administration.
Abstract (Originalsprache)
Aims
Selective serotonin reuptake inhibitors (SSRIs) are indicated for a variety of psychiatric conditions which may require treatment during pregnancy. Knowledge of appropriate SSRI dosages that maintain maternal therapeutic benefit and minimize fetal risk are needed. Assessment of fetal exposure to drugs is challenging since sampling is often limited to a single concentration from the umbilical cord at delivery. Physiologically based pharmacokinetic (PBPK) modelling provides a non‐invasive approach to quantify exposure in pregnancy.
Methods
We incorporated sertraline clearances mediated by passive diffusion, placental efflux transporters P‐glycoprotein (P‐gp) and breast cancer resistance protein (BCRP) into our previously published pregnancy PBPK model for sertraline. Simulations were performed for various sertraline doses (25–200 mg) at 40 weeks gestational age to predict the minimum ( C min ), maximum ( C max ) and average ( C avg ) sertraline maternal and fetal plasma concentrations and evaluated them against observed maternal and cord concentrations obtained at delivery from five clinical studies.
Results
The accuracy of the PBPK predictions as indicated by the average fold error (AFE) value for C max , C min and C avg for maternal plasma sertraline concentrations at delivery was 1.7, 1.2 and 1.4, respectively. The AFE for the C max , C min and C avg for cord blood sertraline concentration at delivery was 1.2, 1 and 1.1, respectively. The AFE for cord‐maternal sertraline concentration ratio at delivery for C max , C min and C avg was 0.7, 0.9 and 0.8, respectively.
Conclusions
The PBPK model we developed may serve as a guide for maternal sertraline dose adjustment during pregnancy considering changes in exposures for both mother and fetus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
- Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee, USA.
- National Center for Toxicological Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
ORCID-Profile: Blessy George
Förderung
- U.S. Food and Drug Administration
Zitieren
APA
Lartey, D., Jateng, D., Li, M., Nguyen, C., Crentsil, V., Beitz, J., & George, B. (2025). Quantification of sertraline maternal/fetal ratio and amniotic fluid concentration using a pregnancy physiologically based pharmacokinetic model. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15826
Vancouver
Lartey D, Jateng D, Li M, Nguyen C, Crentsil V, Beitz J, et al. Quantification of sertraline maternal/fetal ratio and amniotic fluid concentration using a pregnancy physiologically based pharmacokinetic model. British Journal of Clinical Pharmacology. 2025. doi:10.1111/bcp.15826
BibTeX
@article{Lartey2025,
author = {Lartey, David and Jateng, Danielle and Li, Miao and Nguyen, Christine and Crentsil, Victor and Beitz, Julie and George, Blessy},
title = {Quantification of sertraline maternal/fetal ratio and amniotic fluid concentration using a pregnancy physiologically based pharmacokinetic model},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1111/bcp.15826}
}
EUVIMED